Shares of Medidata Solutions Inc. (NASDAQ:MDSO) have been given a consensus rating of “Buy” by the thirteen research firms that are currently covering the stock. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $55.25.
A number of research analysts have commented on the company. Wells Fargo & Co. downgraded Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 21st. Deutsche Bank AG boosted their target price on Medidata Solutions from $56.00 to $58.00 and gave the company a “buy” rating in a research note on Tuesday, September 13th. KeyCorp restated a “buy” rating on shares of Medidata Solutions in a research note on Thursday, July 7th. Zacks Investment Research downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Finally, Needham & Company LLC assumed coverage on Medidata Solutions in a research note on Monday, July 11th. They issued a “buy” rating and a $55.00 target price on the stock.
In other Medidata Solutions news, EVP Eileen Schloss sold 10,644 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $52.82, for a total value of $562,216.08. Following the completion of the sale, the executive vice president now owns 25,765 shares of the company’s stock, valued at $1,360,907.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Vries Glen Michael De sold 32,500 shares of the business’s stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.25, for a total value of $1,600,625.00. Following the completion of the sale, the president now directly owns 1,015,153 shares of the company’s stock, valued at approximately $49,996,285.25. The disclosure for this sale can be found here. 6.70% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in MDSO. FMR LLC boosted its stake in shares of Medidata Solutions by 15.2% in the second quarter. FMR LLC now owns 6,908,046 shares of the company’s stock worth $323,780,000 after buying an additional 913,489 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Medidata Solutions by 4.7% in the second quarter. Vanguard Group Inc. now owns 4,435,841 shares of the company’s stock worth $207,909,000 after buying an additional 200,142 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Medidata Solutions by 3.1% in the second quarter. BlackRock Fund Advisors now owns 3,607,217 shares of the company’s stock worth $169,070,000 after buying an additional 109,795 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Medidata Solutions by 8.4% in the second quarter. Champlain Investment Partners LLC now owns 1,530,610 shares of the company’s stock worth $71,740,000 after buying an additional 118,150 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its stake in shares of Medidata Solutions by 2.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,387,163 shares of the company’s stock worth $65,016,000 after buying an additional 27,799 shares in the last quarter.
Shares of Medidata Solutions (NASDAQ:MDSO) traded down 3.12% during midday trading on Thursday, reaching $54.90. The company’s stock had a trading volume of 129,713 shares. The stock has a market capitalization of $3.05 billion, a P/E ratio of 141.13 and a beta of 1.21. The stock’s 50-day moving average is $54.60 and its 200 day moving average is $47.07. Medidata Solutions has a 12 month low of $30.22 and a 12 month high of $56.76.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Wednesday, July 20th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Medidata Solutions had a return on equity of 10.32% and a net margin of 5.29%. The firm had revenue of $114.60 million for the quarter, compared to the consensus estimate of $112.39 million. During the same quarter in the previous year, the company posted $0.22 earnings per share. The business’s quarterly revenue was up 16.8% compared to the same quarter last year. On average, analysts expect that Medidata Solutions will post $1.01 earnings per share for the current fiscal year.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.